Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28990365 | 0.93 | TDP1 (0.38) | TDP1EPHX1TRPA1ALDH1A1TSHR | |
| SCHEMBL453958 | 0.88 | TDP1 (0.43) | TDP1EPHX1TRPA1ALDH1A1TSHR | |
| SCHEMBL4953348 | 0.82 | CTSK (0.51) | CTSKTAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL106764 | 0.79 | EPHX1 (0.44) | TDP1EPHX1TRPA1ALDH1A1TSHR | |
| SCHEMBL9233306 | 0.79 | CSNK1E (0.53) | CTSKSIGMAR1CTSLCTSB | |
| SCHEMBL7889486 | 0.79 | EPHX1 (0.52) | EPHX1TRPA1TSHRTAAR1SLC6A2 | |
| SCHEMBL22122569 | 0.78 | SIGMAR1 (0.47) | EPHX1TRPA1CTSKTAAR1SLC6A2 | |
| SCHEMBL21268579 | 0.78 | CSNK1E (0.55) | CTSKCTSLCTSB | |
| SCHEMBL21268585 | 0.78 | CSNK1E (0.55) | CTSKCTSLCTSB | |
| SCHEMBL21268584 | 0.78 | CSNK1E (0.55) | CTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038866-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, COATING LIQUID, ARTICLE, AND METHOD FOR PRODUCING ARTICLE | ＡＧＣ株式会社 | 2024-02-22 | — | — | WO | disclosed |
| EP-1796674-B1 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED KV1.3 POTASSIUM CHANNEL | UNIV CALIFORNIA (US) | 2016-02-03 | — | — | EP | disclosed |
| US-8067460-B2 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFONIA (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100121059-A1 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED Kv1.3 POTASSIUM CHANNEL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-13 | — | — | US | disclosed |
| US-7557138-B2 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1796674-A4 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED KV1.3 POTASSIUM CHANNEL | UNIV CALIFORNIA (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7547680-B2 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICALS, CO., LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1796674-A2 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED KV1.3 POTASSIUM CHANNEL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060276444-A1 | Porphyrin-polyamine conjugates for cancer therapy | PROGEN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006041800-A2 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED KV1.3 POTASSIUM CHANNEL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079535-A1 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-13 | — | — | US | disclosed |
| US-7026347-B2 | Porphyrin-polyamine conjugates for cancer therapy | CELLGATE, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1515973-A1 | PORPHYRIN-POLYAMINE CONJUGATES FOR CANCER THERAPY | Cellgate Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040152687-A1 | Porphyrin-polyamine conjugates for cancer therapy | CELLGATE, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004002991-A1 | PORPHYRIN-POLYAMINE CONJUGATES FOR CANCER THERAPY | CELLGATE, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276444-A1 | Porphyrin-polyamine conjugates for cancer therapy | SRM, PAICS, FOLH1 | TDP1 581/4885EPHX1 3573/4885TRPA1 3222/4885 |
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | SLCO1B3, SLCO2A1, SLCO2B1 | TDP1 2326/4885EPHX1 2367/4885TRPA1 2932/4885 |
| US-20100121059-A1 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED Kv1.3 POTASSIUM CHANNEL | KCNA3, KCNJ2, KCNQ1 | TDP1 1207/4885EPHX1 3223/4885TRPA1 128/4885 |
| US-20060079535-A1 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | KCNA3, KCNJ2, KCNQ1 | TDP1 1207/4885EPHX1 3223/4885TRPA1 128/4885 |
| US-20040152687-A1 | Porphyrin-polyamine conjugates for cancer therapy | SRM, PAICS, FOLH1 | TDP1 581/4885EPHX1 3573/4885TRPA1 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.